BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24566578)

  • 1. Prescription size and adherence in the management of psoriasis: is the more, the better?
    Neri L; Vena GA; Cassano N
    G Ital Dermatol Venereol; 2014 Feb; 149(1):152-3. PubMed ID: 24566578
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis.
    Menter A; Abramovits W; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2009 Jan; 8(1):52-7. PubMed ID: 19180896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcipotriene 0.005% and betamethasone dipropionate 0.064% combination topical suspension (Taclonex Scalp).
    Scheinfeld NS
    Skinmed; 2011; 9(3):179-80. PubMed ID: 21675498
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists' preferences for alternative treatment options.
    Neri L; Miracapillo A
    G Ital Dermatol Venereol; 2015 Feb; 150(1):19-26. PubMed ID: 25521808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
    Kreuter A; Sommer A; Hyun J; Bräutigam M; Brockmeyer NH; Altmeyer P; Gambichler T
    Arch Dermatol; 2006 Sep; 142(9):1138-43. PubMed ID: 16983001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vitamin D and scalp psoriasis.
    Koo J
    Cutis; 2002 Nov; 70(5 Suppl):21-4. PubMed ID: 12467336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A betamethasone-calcipotriene combination for psoriasis.
    Med Lett Drugs Ther; 2006 Jul; 48(1238):55-6. PubMed ID: 16841023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Th17 cell fluctuation in psoriatic patients treated with topical calcipotriol and betamethasone butyrate propionate.
    Hino R; Kabashima R; Kawakami C; Sugita K; Nakamura M; Tokura Y
    J Eur Acad Dermatol Venereol; 2011 Feb; 25(2):242-4. PubMed ID: 20477915
    [No Abstract]   [Full Text] [Related]  

  • 9. Topical calcipotriene 0.005% and betamethasone dipropionate 0.064% maintains efficacy of etanercept after step-down dose in patients with moderate-to-severe plaque psoriasis: results of an open label trial.
    Kircik LH
    J Drugs Dermatol; 2011 Aug; 10(8):878-82. PubMed ID: 21818509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clobetasol propionate 0.05% spray on health-related quality of life in patients with plaque psoriasis.
    Menter MA; Caveney SW; Gottschalk RW
    J Drugs Dermatol; 2012 Nov; 11(11):1348-54. PubMed ID: 23135087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to nip "seeding trials" in the bud.
    Katz KA
    Arch Dermatol; 2008 Mar; 144(3):403-4. PubMed ID: 18347299
    [No Abstract]   [Full Text] [Related]  

  • 12. The separate daily application of tacalcitol 4 µg/g ointment and budesonide 0.25 mg/g cream is more effective than the single daily application of a two compound ointment containing calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g.
    Calzavara-Pinton P; Rossi MT; Sala R; Venturini M
    G Ital Dermatol Venereol; 2011 Aug; 146(4):295-9. PubMed ID: 21785396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial.
    Langley RG; Gupta A; Papp K; Wexler D; Østerdal ML; Curčić D
    Dermatology; 2011; 222(2):148-56. PubMed ID: 21293107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland.
    Bottomley JM; Auland ME; Morais J; Boyd G; Douglas WS
    Curr Med Res Opin; 2007 Aug; 23(8):1887-901. PubMed ID: 17610804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nail psoriasis: a combined treatment with 8% clobetasol nail lacquer and tacalcitol ointment.
    Sánchez Regaña M; Márquez Balbás G; Umbert Millet P
    J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):963-9. PubMed ID: 18410337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study.
    Fleming C; Ganslandt C; Guenther L; Johannesson A; Buckley C; Simon JC; Stegmann H; Vestergaard Tingleff L
    Eur J Dermatol; 2010; 20(4):465-71. PubMed ID: 20413372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland.
    Affleck AG; Bottomley JM; Auland M; Jackson P; Ryttov J
    Curr Med Res Opin; 2011 Jan; 27(1):269-84. PubMed ID: 21142836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns of vitamin D analog use for the treatment of psoriasis.
    Ahn CS; Awadalla F; Huang KE; Yentzer B; Dabade TS; Feldman SR
    J Drugs Dermatol; 2013 Aug; 12(8):906-10. PubMed ID: 23986164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steroid swapping between friends: adrenal suppression secondary to psoriasis treatment.
    Hughes R; Gibney J; Kirby B
    Ir J Med Sci; 2009 Jun; 178(2):241-2. PubMed ID: 18989722
    [No Abstract]   [Full Text] [Related]  

  • 20. A multi-center, open-label study to evaluate the safety and efficacy of a sequential treatment regimen of clobetasol propionate 0.05% spray followed by Calcitriol 3 mg/g ointment in the management of plaque psoriasis.
    Brodell RT; Bruce S; Hudson CP; Weiss JS; Colón LE; Johnson LA; Gottschalk RW
    J Drugs Dermatol; 2011 Feb; 10(2):158-64. PubMed ID: 21283920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.